熱門資訊> 正文
诺和诺德因削减指导而面临股东诉讼
2025-08-05 01:37
- Novo Nordisk (NVO) is facing a shareholder lawsuit due to its recent decision to lower its full-year growth outlook for revenue and operating profit, citing headwinds in the GLP-1 market.
- ADRs of the weight loss drugmaker plunged over 20% on Tuesday in reaction to the decision, marking the stock’s sharpest intraday decline since 1987, according to Bloomberg data.
- A group of Novo (NVO) shareholders filed a proposed class action lawsuit in a federal court in New Jersey against the Danish firm on Friday, seeking to recover losses from an alleged securities fraud committed by the company between May 7 and July 28, 2025.
- The plaintiffs alleged that NVO issued exceedingly positive remarks and distributed false and misleading statements regarding its growth potential and hid materially significant adverse facts during that timeframe, creating shareholder losses as the stock plunged following the guidance cut.
More on Novo Nordisk
- Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside
- Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
- Novo Nordisk: Don't Miss Buying This Dip
- Noom launches microdose copies of Novo's Wegovy at $119
- Notable analyst calls this week: Nike, Microsoft and Sarepta among top picks
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
